Benjamin Graham fit · Defensive deep-value investing
Is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) a Benjamin Graham Stock?
Meets only 4/7 Graham criteria — likely overpriced or unstable.
13/100
FNot a fit
4/7 criteria passed
Benjamin Graham's Criteria, Applied to AMRX
P/E ≤ 15
key—
P/B ≤ 1.5
key0.0x
Current ratio ≥ 2
2.1x
Debt / Equity ≤ 1
0.0x
How AMRX Scores on Other Strategies
Live Financial Snapshot
Market cap
$4.21B
P/E (TTM)
-
ROIC (TTM)
9.19%
Gross margin
36.76%
Frequently Asked Questions
What is AMRX's Benjamin Graham fit score?
AMRX scores 13/100 on our Benjamin Graham fit engine — grade F. Meets only 4/7 Graham criteria — likely overpriced or unstable.
Does Benjamin Graham actually own AMRX?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends AMRX.
How often is this score updated?
AMRX's Benjamin Graham fit score is recomputed daily from the latest TTM financials.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends AMRX.